Immunoassay Detects Specific Antibodies in Antiphospholipid Syndrome Patients
By LabMedica International staff writers Posted on 15 Jun 2015 |
Currently, enzyme-linked immunosorbent assays (ELISA) for detection of anticardiolipin (aCL) and anti-β2glycoprotein I (anti-β2GPI) antibodies has not been standardized.
Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies directed against plasma protein-phospholipid complexes or single plasma proteins and their presence in patients with thrombosis and/or pregnancy morbidity defines antiphospholipid syndrome.
Scientists at the University of Padova (Italy) collected blood samples from 94 primary antiphospholipid syndrome (PAPS) patients (84 females and 10 males, mean age 44.3 ± 11.7 years, range 20 to 79) who fulfilled the classification criteria for definite antiphospholipid syndrome. Forty-three had a history of thrombosis, 38 of pregnancy morbidity, and 13 of both thrombosis and pregnancy morbidity.
Serum immunoglobulin G/M (IgG/IgM) aCL/anti-β2GPI antibodies were determined using a fluorescence enzyme immunoassay (FEIA-EliA, Phadia AB; Uppsala, Sweden) and an in-house ELISA. The fluorescence in the reaction mixture was measured using the Phadia 250 instrument. Higher fluorescent signal values corresponded to larger quantities of antibodies binding to the antigens. IgG/IgM aCL and IgG/IgM anti-β2GPI ELISA assays were performed using a home-made method following the European Forum on antiphospholipid (aPL) recommendations.
The sensitivities of the two methods were similar with the exception of IgM aCL which was found to be significantly higher in the PAPS patients using the ELISA method, even if IgM aCL was detected at a low level by both techniques. The two assays had a comparable specificity, a high/significant agreement and a significant correlation between the antibody levels. FEIA testing uncovered no significant prevalence of any antiphospholipid (aPL) antibody in the ELISA negative patients.
The authors concluded that FEIA, like other fully automated systems, may be considered as a useful assay for laboratories with a large number of samples and moreover, it reduces operator handling, pipetting errors and differences in protocols. The results of the study support FEIA's routine use in detecting aCL and anti-β2GPI antibodies. The study was published in the June 2015 issue of the journal Clinica Chimica Acta.
Related Links:
University of Padova
Phadia AB
Antiphospholipid (aPL) antibodies are a heterogeneous group of autoantibodies directed against plasma protein-phospholipid complexes or single plasma proteins and their presence in patients with thrombosis and/or pregnancy morbidity defines antiphospholipid syndrome.
Scientists at the University of Padova (Italy) collected blood samples from 94 primary antiphospholipid syndrome (PAPS) patients (84 females and 10 males, mean age 44.3 ± 11.7 years, range 20 to 79) who fulfilled the classification criteria for definite antiphospholipid syndrome. Forty-three had a history of thrombosis, 38 of pregnancy morbidity, and 13 of both thrombosis and pregnancy morbidity.
Serum immunoglobulin G/M (IgG/IgM) aCL/anti-β2GPI antibodies were determined using a fluorescence enzyme immunoassay (FEIA-EliA, Phadia AB; Uppsala, Sweden) and an in-house ELISA. The fluorescence in the reaction mixture was measured using the Phadia 250 instrument. Higher fluorescent signal values corresponded to larger quantities of antibodies binding to the antigens. IgG/IgM aCL and IgG/IgM anti-β2GPI ELISA assays were performed using a home-made method following the European Forum on antiphospholipid (aPL) recommendations.
The sensitivities of the two methods were similar with the exception of IgM aCL which was found to be significantly higher in the PAPS patients using the ELISA method, even if IgM aCL was detected at a low level by both techniques. The two assays had a comparable specificity, a high/significant agreement and a significant correlation between the antibody levels. FEIA testing uncovered no significant prevalence of any antiphospholipid (aPL) antibody in the ELISA negative patients.
The authors concluded that FEIA, like other fully automated systems, may be considered as a useful assay for laboratories with a large number of samples and moreover, it reduces operator handling, pipetting errors and differences in protocols. The results of the study support FEIA's routine use in detecting aCL and anti-β2GPI antibodies. The study was published in the June 2015 issue of the journal Clinica Chimica Acta.
Related Links:
University of Padova
Phadia AB
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form